Abstract

ROR1 is an Intriguing Target for Cancer Therapy

Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1) is an oncofetal protein and has gained attention in cancer therapy since its initial discovery as a relatively specific surface antigen on B cell chronic lymphocytic leukemia (CLL) in 2008. The list of cancer types with ROR1 expression keeps growing, comprising, among others, malignant melanoma, breast cancer, and prostate cancer. It has been shown that ROR1 mediates several oncogenic pathways in a cancer type- and context-dependent manner. There are several ways to target ROR1 molecule, some of which have been in preclinical and clinical trials. We briefly summarize the oncogenic signaling pathways related to ROR1, as well as the update on ROR1-targeted therapies.


Author(s):

Ryan Kolb, Paige Kluz and Weizhou Zhang



Abstract | Full-Text | PDF

Share this  Facebook  Twitter  LinkedIn  Google+
Flyer image

Abstracted/Indexed in

  • Google Scholar
  • Publons